Enbrel 'loses out' to Humira in first-line psoriasis battle
This article was originally published in Scrip
Enbrel (etanercept; Amgen/Pfizer/Stiefel/Takeda) has been replaced by Humira (adalimumab; Abbott/Eisai) as the preferred first-line therapy in moderate to severe psoriasis, according to primary research recently conducted by Datamonitor Healthcare. The research also suggests that Stelara is gaining ground, while the field is being prepared for the advent of biosimilars.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.